SANTARIS PHARMACEUTICALS
Similar Organizations
Aju Pharma
South Korean pharmaceutical company.
More informations about "Santaris Pharmaceuticals"
Santaris Pharma - Crunchbase Company Profile
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The …See details»
Santaris Pharma Company Profile | Management and Employees …
The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company's proprietary LNA chemistries with its highly specialized and targeted drug …See details»
Santaris Pharmaceuticals - Crunchbase Company Profile & Funding
Organization. Santaris Pharmaceuticals . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. A biopharmaceutical company. …See details»
Santaris Pharma - Gilde Healthcare
Santaris Pharma discovers and develops RNA-targeted therapies to treat infectious diseases and metabolic disorders. Through its partnerships with pharmaceutical companies, Santaris covers a range of therapeutic areas …See details»
Santaris Pharma - Products, Competitors, Financials, Employees ...
Santaris Pharma is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine …See details»
Santaris Pharma - VentureRadar
Santaris Pharma A/S is a clinical stage biopharmaceutical company developing next generation RNA-silencing drugs for the treatment of cancer and metabolic diseases. The company, which …See details»
Santaris Pharma - PitchBook
Santaris Pharma General Information Description. Developer of ribonucleic acid (RNA) targeted therapies. The company's Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery …See details»
Roche continues dealmaking with acquisition of Santaris
Aug 4, 2014 Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group. Roche said that the privately held Danish biotech group’s so-called locked ...See details»
Roche to acquire Santaris Pharma to expand discovery and …
Aug 5, 2014 Santaris Pharma A/S uses its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise to pioneer next-generation antisense product candidates. Santaris …See details»
Santaris Pharma - Funding, Financials, Valuation & Investors
Santaris Pharma is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. Search Crunchbase. Start Free Trial . Chrome Extension. ... How …See details»
Roche returns to gene silencing with Santaris acquisition
Aug 6, 2014 Roche has just announced a $450m deal to acquire Danish company Santaris Pharma, a specialist in a form of antisense therapy that switches off a gene by interacting with …See details»
Roche to acquire Santaris Pharma to expand discovery and …
Aug 4, 2014 Santaris Pharma's innovation and leadership position has attracted multiple collaborations with leading global pharmaceutical companies. Founded in 2003, Santaris …See details»
Roche to acquire Santaris Pharma - bionity.com
Aug 6, 2014 Roche plans to maintain Santaris Pharma’s operations in Denmark, where the existing site will be renamed Roche Innovation Center Copenhagen. Under the terms of the …See details»
Roche Acquiring Santaris Pharma for Up to $450M
Aug 4, 2014 The platform has attracted interest from pharma and biotech partners. In April 2013, Bristol-Myers Squibb launched an up-to-$100 million-plus partnership with Santaris Pharma to …See details»
Enzon Pharmaceuticals and Santaris Pharma Enter into Global ...
BRIDGEWATER, N.J. & COPENHAGEN, Denmark, Jul 27, 2006 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) and Santaris Pharma A/S (private) announced today …See details»
Roche to buy Santaris Pharma - nordiclifescience.org
Aug 5, 2014 Swiss Roche has announced that the company has agreed to acquire Danish biopharmaceutical firm Santaris Pharma for USD 450 million. The Magazine Advertising About …See details»
SANTARIS PHARMA - New data show breakthrough ... - Gilde …
Dec 3, 2009 The World Health Organization estimates about 3% of the world’s population has been infected with HCV and that some 170 million are chronic carriers at risk of developing …See details»
Santaris Pharma A/S and miRagen Therapeutics, Inc. Form …
Jun 23, 2010 The unique combination of pharmaceutical properties, small size and very high affinity of LNA-based drugs developed utilizing Santaris Pharma A/S LNA Drug Platform …See details»
Santaris Pharma A/S Obtains Exclusive License from Mass General ...
Feb 28, 2011 /PRNewswire/ -- Santaris Pharma A/S, ... According to the World Health Organization, cardiovascular diseases are the number one cause of death globally and by …See details»